Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alprazolam
Drug ID BADD_D00085
Description Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.[A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.[A18125] Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death.[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148]
Indications and Usage Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults.[L34783] Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.[L34783, L34788] Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.[A177973]
Marketing Status approved; illicit; investigational
ATC Code N05BA12
DrugBank ID DB00404
KEGG ID D00225
MeSH ID D000525
PubChem ID 2118
TTD Drug ID D0L9GG
NDC Product Code 72789-151; 49452-0295; 0009-0055; 45865-972; 49884-213; 0228-2039; 0228-3084; 53002-3952; 59762-3719; 60760-550; 63187-966; 68071-2220; 68071-5243; 68788-7595; 70518-2870; 70518-3763; 71335-1386; 71335-1669; 71335-9666; 71335-9667; 71610-696; 72189-213; 0228-2031; 65862-678; 49884-110; 51991-706; 0228-3086; 53002-0340; 59762-0066; 59762-3722; 60760-678; 65862-677; 67296-1748; 68071-2976; 68788-7596; 0054-3068; 71205-652; 71335-0849; 71335-1576; 71335-1839; 72189-240; 72789-313; 0781-1079; 80425-0110; 42816-0055; 42816-0094; 65862-454; 65862-457; 71554-013; 59762-0057; 61919-005; 63187-444; 63187-445; 63187-916; 65162-813; 68071-2965; 71205-284; 71205-718; 71335-1907; 65162-810; 71335-1291; 71610-112; 0615-8295; 0228-2029; 12780-4630; 64330-013; 0009-0068; 49884-214; 50090-2819; 50090-5258; 0228-2027; 51991-705; 51991-707; 59762-3721; 65862-676; 67296-0757; 67544-414; 68071-2236; 68071-2794; 70518-3259; 70954-510; 71205-614; 71335-1894; 72189-121; 72189-450; 0781-1061; 12828-0040; 42816-0029; 42816-0057; 0009-0057; 0009-0059; 43063-609; 45865-424; 50090-5262; 0228-4019; 0228-4022; 55700-929; 59762-0059; 59762-3720; 63187-443; 65862-456; 68071-2292; 68071-4831; 70954-509; 70954-511; 71205-227; 71335-1477; 80425-0161; 0009-5144; 42816-0090; 65015-634; 65862-679; 0009-0066; 50090-5078; 51991-704; 0228-3083; 67544-415; 68071-5263; 68788-8410; 70518-2785; 70518-3730; 0781-1077; 80425-0099; 80425-0100; 80425-0284; 42816-0059; 42816-0066; 42816-0068; 63187-518; 68071-5113; 68071-5128; 68788-7613; 68788-9682; 71335-1092; 71610-113; 72789-042; 83008-010; 65862-455; 0009-0029; 0009-0090; 45865-993; 49884-111; 0228-4024; 63187-971; 65162-809; 65162-812; 68788-7594; 68788-8394; 71335-2133; 71335-9660; 49999-252; 50090-2896; 50090-5261; 63187-225; 67544-347; 68071-2966; 68788-8414; 70954-508; 71335-0427; 71335-0920; 71335-1129; 72162-1059; 72789-024; 72789-328; 0781-1089; 57218-312; 0009-0094; 0228-3087; 0228-4025; 53002-4181; 55289-523; 59762-0068
UNII YU55MQ3IZY
Synonyms Alprazolam | Alprazolan | Trankimazin | U-31,889 | U31,889 | Xanax | Alprox | Esparon | Cassadan | D-65MT | D65MT | Kalma | Novo-Alprazol | Novo Alprazol | Nu-Alpraz | Nu Alpraz | Ralozam | Tafil | Apo-Alpraz | Apo Alpraz
Chemical Information
Molecular Formula C17H13ClN4
CAS Registry Number 28981-97-7
SMILES CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Negative thoughts19.15.02.0120.000019%-
Sopor17.02.04.021; 19.02.04.0020.005828%-
Foot deformity15.10.03.0050.000019%-
Vagus nerve disorder17.04.06.0040.000029%
Foaming at mouth07.05.05.019; 08.01.03.070; 17.02.05.0560.000019%-
Neurodevelopmental disorder17.02.10.031; 19.22.02.0030.000019%-
Stress cardiomyopathy02.04.01.012; 24.04.04.0260.000068%-
Acute lung injury22.01.03.0100.000019%-
Hyporesponsive to stimuli17.02.05.0570.000058%-
Neonatal behavioural syndrome15.05.04.020; 17.02.05.058; 18.04.04.010; 22.11.02.0070.000029%-
Disorganised speech17.02.08.017; 19.19.02.0050.000019%-
Infantile apnoea18.04.15.003; 22.11.02.0040.000019%-
Selective eating disorder14.03.02.024; 19.09.01.0120.000019%-
Acquired amegakaryocytic thrombocytopenia01.08.01.011; 10.02.01.0660.000019%-
Allergic reaction to excipient10.01.01.0350.000066%-
Anamnestic reaction10.02.01.0680.000039%-
Behaviour disorder19.01.01.0050.000146%-
Cardio-respiratory arrest neonatal02.03.04.023; 18.04.17.004; 22.11.02.0130.000019%-
Coronary no-reflow phenomenon02.02.02.025; 24.04.04.0300.000029%-
Dilated cardiomyopathy02.04.01.0170.000029%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.000392%-
Drug use disorder19.07.06.0120.001378%-
Glossopharyngeal nerve disorder17.04.11.0010.000029%
Hepatic cytolysis09.01.07.0360.000078%-
Illness08.01.03.091---
Illogical thinking19.10.03.0120.000029%-
Lung opacity22.12.01.0060.000029%-
Mixed anxiety and depressive disorder19.15.01.0100.000029%-
Myocardial injury02.04.02.0460.000039%-
Papillary muscle disorder02.04.02.0470.000039%-
The 19th Page    First    Pre   19 20    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene